logo
Share SHARE
FONT-SIZE Plus   Neg

Reports: Amylin Seeks Buyers

Amylin Pharmaceuticals Inc. (AMLN: Quote), which rejected a $3.5 billion unsolicited takeover offer from Bristol-Myers Squibb Co. (BMY) in late March, has reportedly hired advisers to seek a sale of the company, reports said Sunday.

Early this month, activist investor Carl Icahn had filed a lawsuit against the diabetes drug maker to put pressure on it to pursue a deal to sell the company. Icahn owns about 9 percent of Amylin's shares.

Reports sugest that Credit Suisse Group AG and Goldman Sachs Group Inc. have been hired by the maker of Bydureon and Byetta as financial advisers on a potential sale. The company is said to have begun approaching potential buyers last week.

Several drugmakers, including France's Sanofi (SNY), could be mulling an offer for Amylin. Sanofi, though is discussing a bid internally, is said to be hesitant because Byetta will directly compete with the French drugmaker's experimental treatment lixisenatide.

AMLN closed on Friday at $22.92, down $0.15 or 0.66 percent, on a volume of 3.42 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
International Business Machines Corp. said Monday after the markets closed that its first quarter profit fell 2.4% from last year, as improved margins could not offset a 12% decrease in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Norway is all set to shut down FM radio in 2017, Radio.no reported. The Nordic country will be the first to scrap as it plans a shift to Digital Audio Broadcasting. The trailer of Star Wars: The Force Awakens, the latest installment from epic space film franchisee created by George Lucas, has sent both fans and Disney investors into a frenzy. Walt Disney Co.'s (DIS) market capitalization, which now owns the Star Wars franchisee, was boosted by about $2 billion...
comments powered by Disqus
Follow RTT